MeSH tree: C20.683.515
Survivors of hematologic cancers are at high risk of developing cardiovascular disease (CVD), according to a study published online June 22 in BMC Cancer.
Jun 30, 2026
0
4
After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy ...
Jun 25, 2026
0
13
Researchers at the Icahn School of Medicine at Mount Sinai have found that wearable devices may help clinicians detect cytokine release syndrome (CRS)—a common and potentially serious side effect of CAR-T cell therapy—hours ...
Jun 22, 2026
0
6
UK media celebrity Jeremy Clarkson this week revealed he has been diagnosed with an aggressive form of prostate cancer.
Jun 18, 2026
0
15
Patients with multiple myeloma who received a new immunotherapy combination lived significantly longer without their cancer worsening and showed early signs of improved survival in a large international clinical trial.
Jun 15, 2026
0
5
Researchers at the University of Maryland School of Medicine (UMSOM) have identified a target that may improve the response to CAR T-cell therapy, a treatment for patients with recurrent or difficult-to-treat blood cancers.
Jun 15, 2026
0
4
Triplet therapy with pirtobrutinib, venetoclax and rituximab as a two-year fixed-duration therapy improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with standard-of-care ...
Jun 15, 2026
0
4
Scientists at Florida International University may have found a way to make a powerful cancer treatment work even better. The treatment, called CAR-T therapy, uses a patient's own immune cells to fight cancer. Doctors remove ...
Jun 13, 2026
0
10
Chimeric antigen receptor T-cell therapy, or CAR-T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to recognize and attack tumor cells. It offers many patients ...
Jun 7, 2026
0
8
A new study has uncovered why many patients with relapsed diffuse large B-cell lymphoma (rDLBCL) fail to respond as well as expected to newly approved cancer therapies. Patients treated with novel therapies in routine practice ...
Jun 1, 2026
0
3
